Infusion Pumps Total Product Life Cycle; Guidance for Industry and Food and Drug Administration Staff; Availability, 71434-71435 [2014-28267]
Download as PDF
71434
Federal Register / Vol. 79, No. 231 / Tuesday, December 2, 2014 / Notices
I. Background
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–D–0194]
Infusion Pumps Total Product Life
Cycle; Guidance for Industry and Food
and Drug Administration Staff;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
Food and Drug
Administration (FDA) is announcing the
availability of the final guidance
entitled, ‘‘Infusion Pumps Total Product
Life Cycle; Guidance for Industry and
FDA Staff.’’ The recommendations in
this guidance are intended to improve
the safety and effectiveness of these
devices. This guidance also describes
considerations in preparing premarket
submissions for infusion pumps and
identifies device features that
manufacturers should address
throughout the total product life cycle.
DATES: Submit either electronic or
written comments on this guidance at
any time. General comments on Agency
guidance documents are welcome at any
time.
ADDRESSES: An electronic copy of the
guidance document is available for
download from the Internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the guidance
document entitled ‘‘Infusion Pumps
Total Product Life Cycle; Guidance for
Industry and FDA Staff’’ to the Office of
the Center Director, Guidance and
Policy Development, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5431, Silver Spring,
MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your request.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852. Identify comments with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Alan Stevens, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 2561, Silver Spring,
MD 20993–0002, 301–796–6294.
SUPPLEMENTARY INFORMATION:
rljohnson on DSK3VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
15:30 Dec 01, 2014
Jkt 235001
FDA has evaluated a broad spectrum
of infusion pumps across manufacturers
and has encountered common problems
with device software, human factors,
reliability, and manufacturing. Based on
an evaluation of reported adverse events
and recalls, FDA believes that many
injuries and adverse events may be
avoided by improving the design
verification and validation processes for
infusion pump devices.
The most frequently reported infusion
pump device problems are: Software
error messages, human factors (which
include, but are not limited to, use
error), broken components, battery
failure, alarm failure, over-infusion, and
under-infusion. Subsequent analyses
revealed that many of these design
problems could be corrected during the
design validation and verification
processes.
The Agency believes that this
guidance provides recommendations
that will help mitigate observed risk and
reduce potential risk associated with
infusion pumps. One method of
improving the safety of infusion pumps
is the inclusion of safety assurance cases
as part of the premarket submissions for
new, changed, or modified infusion
pumps submitted by device
manufacturers. This guidance explains
the Agency’s current thinking and
provides recommendations on
information to submit through the safety
assurance case framework and
postmarket surveillance of infusion
pumps.
In April 2010, the Agency issued the
special control draft guidance entitled
‘‘Draft Guidance for Industry and FDA
Staff: Total Product Life Cycle: Infusion
Pump—Premarket Notification [510(k)]
Submissions’’ (Ref. 1). The Agency has
reviewed the comments submitted for
the 2010 guidance and has incorporated
most of the recommendations in this
final guidance.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
This guidance represents the Agency’s
current thinking on infusion pumps. It
does not create or confer any rights for
or on any person and does not operate
to bind FDA or the public. An
alternative approach may be used if
such approach satisfies the
requirements of the applicable statute
and regulations.
III. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
downloading an electronic copy from
the Internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.regulations.gov. Persons
unable to download an electronic copy
of ‘‘Total Product Life Cycle: Infusion
Pumps; Guidance for Industry and FDA
Staff’’ may send an email request to
CDRH-Guidance@fda.hhs.gov to receive
an electronic copy of the document.
Please use the document number 1780
to identify the guidance you are
requesting.
IV. Paperwork Reduction Act
Under the Paperwork Reduction Act
(44 U.S.C. 3501–3520), Federal Agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. This guidance also refers to
previously approved information
collections found in FDA regulations.
The collections of information in 21
CFR part 803 are approved under OMB
control number 0910–0437; the
collections of information in 21 CFR
part 801 are approved under OMB
control number 0910–0485; the
collections of information in 21 CFR
part 812 are approved under OMB
control number 0910–0078; the
collections of information in 21 CFR
part 807, subpart E are approved under
OMB control number 0910–0120; the
collections of information in 21 CFR
part 820 are approved under OMB
control number 0910–0073; the
collections of information in 21 CFR
part 822 are under OMB control number
0910–0449; the collections of
information in 21 CFR 56.115 are
approved under OMB control number
0910–0130; and the collections of
information for safety assurance cases
are approved under OMB control
number 0910–0766.
V. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
E:\FR\FM\02DEN1.SGM
02DEN1
Federal Register / Vol. 79, No. 231 / Tuesday, December 2, 2014 / Notices
VI. Reference
The following reference has been
placed on display in the Division of
Dockets Management (see ADDRESSES),
and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday, and is available
electronically at https://
www.regulations.gov. (FDA has verified
the Web site address in this reference
section, but we are not responsible for
any subsequent changes to the Web site
after this document publishes in the
Federal Register.)
1. The FDA guidance entitled ‘‘Draft
Guidance for Industry and FDA
Staff: Total Product Life Cycle:
Infusion Pump—Premarket
Notification [510(k)] Submissions,’’
available at https://www.fda.gov/
medicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/
ucm206153.htm.
Dated: November 25, 2014.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2014–28267 Filed 12–1–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–D–0295]
Guidance for Industry on Scale-Up
Post-Approval Changes:
Manufacturing Equipment Addendum;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a scale-up and postapproval changes (SUPAC) guidance for
industry entitled ‘‘SUPAC:
Manufacturing Equipment Addendum.’’
This replaces the draft guidance of the
same name that combined and
superseded ‘‘SUPAC IR/MR: Immediate
Release and Modified Release Solid Oral
Dosage Forms: Manufacturing
Equipment Addendum,’’ published on
January 1, 1999; and ‘‘SUPAC–SS:
Nonsterile Semisolid Dosage Forms;
Manufacturing Equipment Addendum,’’
published as a draft on December 1,
1998. FDA revised the draft
manufacturing equipment addenda to
remove the equipment examples and to
clarify the types of processes being
referenced.
rljohnson on DSK3VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
15:30 Dec 01, 2014
Submit either electronic or
written comments on Agency guidances
at any time.
ADDRESSES: Submit written requests for
single copies of the guidance to the
Food and Drug Administration, 10001
New Hampshire Ave., Hillandale
Building, 4th Floor, Silver Spring, MD
20993. Send one self-addressed
adhesive label to assist that office in
processing your requests. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the guidance
document.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
Akm Khairuzzaman, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 301–796–3886.
SUPPLEMENTARY INFORMATION:
DATES:
Jkt 235001
I. Background
FDA is announcing the availability of
a SUPAC guidance for industry entitled
‘‘SUPAC: Manufacturing Equipment
Addendum.’’ This guidance replaces the
draft guidance of the same name that
superseded the following guidances for
industry: (1) ‘‘SUPAC IR/MR: Immediate
Release and Modified Release Solid Oral
Dosage Forms: Manufacturing
Equipment Addendum,’’ published on
January 1, 1999, and (2) ‘‘SUPAC–SS:
Nonsterile Semisolid Dosage Forms;
Manufacturing Equipment Addendum,
‘‘published as draft on December 1,
1998. When published, these guidances
included tables that listed specific
equipment that were misinterpreted as a
list of FDA required equipment. In
addition, FDA is concerned that the
equipment addenda may no longer
reflect current practices and may be
limiting, instead of encouraging,
manufacturers to continually evaluate
and update practices. FDA has removed
the tables listing specific manufacturing
equipment from these guidances and
combined them into a single addendum.
FDA has also made some changes to
clarify the types of processes being
referenced.
This guidance should be used with
the following guidances for industry to
determine what documentation should
be submitted to FDA regarding
equipment changes: (1) ‘‘SUPAC–IR:
Immediate Release Solid Oral Dosage
Forms—Scale-Up and Post-Approval
Changes: Chemistry, Manufacturing and
PO 00000
Frm 00060
Fmt 4703
Sfmt 9990
71435
Controls, In Vitro Dissolution Testing,
and In Vivo Bioequivalence
Documentation,’’ (2) ‘‘SUPAC–MR:
Modified Release Solid Oral Dosage
Forms Scale-Up and Post-Approval
Changes: Chemistry, Manufacturing and
Controls; In Vitro Dissolution Testing
and In Vivo Bioequivalence
Documentation,’’ and (3) ‘‘SUPAC–SS:
Nonsterile Semisolid Dosage Forms,
Scale-Up and Post Approval Changes:
Chemistry Manufacturing and Controls;
In Vitro Release Testing and In Vivo
Bioequivalence Documentation.’’
As part of a greater effort, FDA is
thoroughly reviewing the SUPAC
guidance series to determine how these
guidances fit with current
manufacturing practices, including, but
not limited to, risk-based assessment
approaches and quality by design
principles. This guidance is being
issued consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). This guidance represents the
Agency’s current thinking on
manufacturing equipment. It does not
create or confer any rights for or on any
person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statutes and regulations.
II. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
III. Electronic Access
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm or https://
www.regulations.gov.
Dated: November 25, 2014.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2014–28256 Filed 12–1–14; 8:45 am]
BILLING CODE 4164–01–P
E:\FR\FM\02DEN1.SGM
02DEN1
Agencies
[Federal Register Volume 79, Number 231 (Tuesday, December 2, 2014)]
[Notices]
[Pages 71434-71435]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-28267]
[[Page 71434]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-D-0194]
Infusion Pumps Total Product Life Cycle; Guidance for Industry
and Food and Drug Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Food and Drug Administration (FDA) is announcing the
availability of the final guidance entitled, ``Infusion Pumps Total
Product Life Cycle; Guidance for Industry and FDA Staff.'' The
recommendations in this guidance are intended to improve the safety and
effectiveness of these devices. This guidance also describes
considerations in preparing premarket submissions for infusion pumps
and identifies device features that manufacturers should address
throughout the total product life cycle.
DATES: Submit either electronic or written comments on this guidance at
any time. General comments on Agency guidance documents are welcome at
any time.
ADDRESSES: An electronic copy of the guidance document is available for
download from the Internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the guidance document entitled
``Infusion Pumps Total Product Life Cycle; Guidance for Industry and
FDA Staff'' to the Office of the Center Director, Guidance and Policy
Development, Center for Devices and Radiological Health, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver
Spring, MD 20993-0002. Send one self-addressed adhesive label to assist
that office in processing your request.
Submit electronic comments on the guidance to https://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852. Identify comments with the docket number
found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Alan Stevens, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 2561, Silver Spring, MD 20993-0002, 301-796-6294.
SUPPLEMENTARY INFORMATION:
I. Background
FDA has evaluated a broad spectrum of infusion pumps across
manufacturers and has encountered common problems with device software,
human factors, reliability, and manufacturing. Based on an evaluation
of reported adverse events and recalls, FDA believes that many injuries
and adverse events may be avoided by improving the design verification
and validation processes for infusion pump devices.
The most frequently reported infusion pump device problems are:
Software error messages, human factors (which include, but are not
limited to, use error), broken components, battery failure, alarm
failure, over-infusion, and under-infusion. Subsequent analyses
revealed that many of these design problems could be corrected during
the design validation and verification processes.
The Agency believes that this guidance provides recommendations
that will help mitigate observed risk and reduce potential risk
associated with infusion pumps. One method of improving the safety of
infusion pumps is the inclusion of safety assurance cases as part of
the premarket submissions for new, changed, or modified infusion pumps
submitted by device manufacturers. This guidance explains the Agency's
current thinking and provides recommendations on information to submit
through the safety assurance case framework and postmarket surveillance
of infusion pumps.
In April 2010, the Agency issued the special control draft guidance
entitled ``Draft Guidance for Industry and FDA Staff: Total Product
Life Cycle: Infusion Pump--Premarket Notification [510(k)]
Submissions'' (Ref. 1). The Agency has reviewed the comments submitted
for the 2010 guidance and has incorporated most of the recommendations
in this final guidance.
II. Significance of Guidance
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). This guidance represents the
Agency's current thinking on infusion pumps. It does not create or
confer any rights for or on any person and does not operate to bind FDA
or the public. An alternative approach may be used if such approach
satisfies the requirements of the applicable statute and regulations.
III. Electronic Access
Persons interested in obtaining a copy of the guidance may do so by
downloading an electronic copy from the Internet. A search capability
for all Center for Devices and Radiological Health guidance documents
is available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance
documents are also available at https://www.regulations.gov. Persons
unable to download an electronic copy of ``Total Product Life Cycle:
Infusion Pumps; Guidance for Industry and FDA Staff'' may send an email
request to CDRH-Guidance@fda.hhs.gov to receive an electronic copy of
the document. Please use the document number 1780 to identify the
guidance you are requesting.
IV. Paperwork Reduction Act
Under the Paperwork Reduction Act (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor. This
guidance also refers to previously approved information collections
found in FDA regulations. The collections of information in 21 CFR part
803 are approved under OMB control number 0910-0437; the collections of
information in 21 CFR part 801 are approved under OMB control number
0910-0485; the collections of information in 21 CFR part 812 are
approved under OMB control number 0910-0078; the collections of
information in 21 CFR part 807, subpart E are approved under OMB
control number 0910-0120; the collections of information in 21 CFR part
820 are approved under OMB control number 0910-0073; the collections of
information in 21 CFR part 822 are under OMB control number 0910-0449;
the collections of information in 21 CFR 56.115 are approved under OMB
control number 0910-0130; and the collections of information for safety
assurance cases are approved under OMB control number 0910-0766.
V. Comments
Interested persons may submit either electronic comments regarding
this document to https://www.regulations.gov or written comments to the
Division of Dockets Management (see ADDRESSES). It is only necessary to
send one set of comments. Identify comments with the docket number
found in brackets in the heading of this document. Received comments
may be seen in the Division of Dockets Management between 9 a.m. and 4
p.m., Monday through Friday, and will be posted to the docket at https://www.regulations.gov.
[[Page 71435]]
VI. Reference
The following reference has been placed on display in the Division
of Dockets Management (see ADDRESSES), and may be seen by interested
persons between 9 a.m. and 4 p.m., Monday through Friday, and is
available electronically at https://www.regulations.gov. (FDA has
verified the Web site address in this reference section, but we are not
responsible for any subsequent changes to the Web site after this
document publishes in the Federal Register.)
1. The FDA guidance entitled ``Draft Guidance for Industry and FDA
Staff: Total Product Life Cycle: Infusion Pump--Premarket Notification
[510(k)] Submissions,'' available at https://www.fda.gov/medicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm206153.htm.
Dated: November 25, 2014.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2014-28267 Filed 12-1-14; 8:45 am]
BILLING CODE 4164-01-P